Cover Page

Cite item


The influenza virus is highly contagious diseases of people, birds and mammals. Approximately 250 000– 500 000 deaths are caused by influenza epidemics worldwide yearly, and the death number may be up to millions in a possible influenza pandemic. Vaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the development and production of pandemic influenza vaccines are response time and production capacity as well as vaccine efficacy and safety. Reverse genetics techniques can speed up the generation of seed viruses and new mathematical modelling methods improve vaccine strain selection. Using vaccines based on recombinant proteins, we avoid the risks associated with the introduction of the virus into the body, even inactivated. In this paper, we have got a highly purified recombinant fusion protein composed of fragments of the hemagglutinin of influenza viruses A and B. As adjuvant we used components of flagellin. We used the most immunogenic and conserved areas of hemagglutinin H1, H3, H5 and B, which cause the formation of specific antibodies which can cross-react with homologous epitopes among the various strains of influenza A and B. Vaccine efficacy is increased by using multiple epitopes of various proteins. The aim of this study was to clone and express the hybrid recombinant protein Flu-Chim, containing immunogenic epitopes of influenza A/H1N1, A/H3N2, A/H5N1 and B fused with fragments of flagellin in Escherichia coli expression system and its subsequent purification. During the study was created high-yield E. coli strain, which produces the recombinant protein Flu-Chim, selected the optimal protocol of induction of the gene encoding the protein. The protein was purified using metal affinity chromatography. The purity of the final preparation reached 98%. In the future, we are going to study the immunogenic properties of the protein and use it as a component of the candidate vaccine against influenza.

About the authors

I. V. Dukhovlinov

LLC ATG Service-Gene

Author for correspondence.

PhD (Biology), Director of Science,

St. Petersburg

Russian Federation

O. A. Dobrovolskaia

Institute of Experimental Medicine


PhD Student,

197376, St. Petersburg, Akademika Pavlova str., 12

Russian Federation

A. I. Orlov

LLC Universal Biosystems


PhD, MD (Chemistry), General Director,

St. Petersburg

Russian Federation


  1. Эпидемиологическая ситуация. ФГБУ НИИ гриппа Министерства здравоохранения России, 2016. [Epidemiologicheskaya situatsiya [Epidemic Situation]. Research Institute of Influenza, Ministry of healthcare of the Russian Federation, 2016]. URL: (05.04.2017)
  2. Balaram P., Kien P.K., Ismail A. Toll-like receptors and cytokines in immune responses to persistent mycobacterial and Salmonella infections. Int. J. Med. Microbiol., 2009, vol. 299, no. 3, pp. 177–185.
  3. Griffin M.R. Influenza vaccination: a 21st century dilemma. S. D. Med., 2013, special no., pp. 110–118.
  4. Henry M., Larrinua I.M., Russell S.M. Novel DNA sequences, vectors and proteins of avian influenza hemagglutinin: pat. US20090106864 A1, April 23, 2009.
  5. Influenza. Surveillance and monitoring. World Health Organization, 2016.
  6. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, vol. 227, no. 5259, pp. 680–685.
  7. Li S., Zhu W. Influenza-pandemic influenza bivalent combined vaccine and preparation method thereof: pat. CN101524538 A USA.
  8. Majumder K. Ligation-free gene synthesis by PCR: synthesis and mutagenesis at multiple loci of a chimeric gene encoding OmpA signal peptide and hirudin. Gene, 1992, vol. 110, no. 1, pp. 89–94.
  9. McCullers J.A. The role of punctuated evolution in the pathogenicity of influenza viruses. Microbiol. Spectr., 2016. vol. 4, no. 2.
  10. Ni-NTA purification system. User manual. Catalog nos. K950-01, K951-01, K952-01, K953-01, K954-01, R901-01, R901-10, R901-15. Version C. 25-0496. Invitrogen, 2006.
  11. Penghui Y., Xiliang W., Deyan L., Yueqiang D., Li X., Jincheng W. Transdermal immune influenza multivalent vaccine and preparation method thereof: pat. CN101450209 B USA. China.
  12. Situation Update: Summary of Weekly FluView Report. Centers for Desease Control and Prevention, 2016.
  13. Smith G.E., Volvovitz F., Wilkinson B.E., Hackett C.S. Method for producing influenza hemagglutinin multivalent vaccines using baculovirus: pat. US5762939 A USA.
  14. Studier F.W. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 2005. vol. 41, no. 1. pp. 207–234.

Copyright (c) 2017 Dukhovlinov I.V., Dobrovolskaia O.A., Orlov A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies